CNS Pharmaceuticals Files 8-K Report

Ticker: CNSP · Form: 8-K · Filed: Apr 9, 2025 · CIK: 1729427

Cns Pharmaceuticals, Inc. 8-K Filing Summary
FieldDetail
CompanyCns Pharmaceuticals, Inc. (CNSP)
Form Type8-K
Filed DateApr 9, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: corporate-disclosure, 8-k

TL;DR

CNS Pharmaceuticals filed an 8-K on 4/9/25, updating its corporate information.

AI Summary

On April 9, 2025, CNS Pharmaceuticals, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 2100 West Loop South, Suite 900, Houston, Texas 77027. The report was filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Why It Matters

This 8-K filing serves as a public notification of the company's operational and reporting status with the SEC.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not contain new financial or operational information that would indicate increased risk.

Key Players & Entities

  • CNS Pharmaceuticals, Inc. (company) — Registrant
  • 2100 West Loop South, Suite 900, Houston, Texas 77027 (location) — Principal executive offices
  • April 9, 2025 (date) — Date of earliest event reported

FAQ

What is the purpose of this 8-K filing for CNS Pharmaceuticals, Inc.?

The 8-K filing is a current report filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, indicating a significant event or update for the company.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on April 9, 2025.

Where are the principal executive offices of CNS Pharmaceuticals, Inc. located?

The principal executive offices of CNS Pharmaceuticals, Inc. are located at 2100 West Loop South, Suite 900, Houston, Texas 77027.

What is the state of incorporation for CNS Pharmaceuticals, Inc.?

CNS Pharmaceuticals, Inc. is incorporated in Nevada.

What is the company's telephone number as listed in the filing?

The company's telephone number, including area code, is (800) 946-9185.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 9, 2025 regarding CNS Pharmaceuticals, Inc. (CNSP).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.